A track record of prior competency that is above and beyond the norm is what hiring managers look for when they recruit "top talent", as recruiters like to say. Usually "top talents" can command a premium in the market place because everybody wants to employ them. We can equate these "top talents" to top quality stocks. You often hear dividend investors talk about how top dividend growth stocks are "always too expensive". That comment usually refers to the yield for the stock being lower than average, which in the case of a quality stock just represents a greater anticipation of future growth.
IBM Watson Health and medical imaging contrast agent company Guerbet have entered a strategic partnership to develop artificial intelligence (AI) software to support liver cancer diagnostics and care by utilizing CT and MRI technology. The collaboration will have Guerbet and IBM Watson Health co-develop clinical decision support solutions including Watson Imaging Care Advisor for Liver, a diagnostic support tool that will utilize AI to automate the detection, staging, tracking, monitoring, therapy prediction and response of primary and second liver cancer for clinicians, according to a Guerbet press release published July 10. "Imaging is a critical area of healthcare where we believe artificial intelligence can be used to expand the physician's view so they can be more informed in their diagnostic and treatment decisions for their patients," said Anne Le Grand, vice president of imaging at IBM Watson Health.
IBM companies Watson Health and Merge Healthcare unveiled several new machine learning and artificial intelligence technologies for imaging at the RSNA Annual meeting in Chicago this week. Big Blue also showcased new advancements in how Watson technology can learn and gain understanding from image information, which researchers say now accounts for some 90 percent of all medical data. IBM has taken a keen insight in applying Watson's supercomputing capabilities to imaging – especially since its 2015 acquisition of Merge. Big Blue, in fact, is developing numerous tools to help automate analytics, enabling cross-reference X-rays, MRIs and other images against electronic health record data, lab results, genomic tests and more. At RSNA, Watson Health is showcasing: a cognitive peer review tool aimed at reconciling differences between a patient's clinical evidence and data in his or her EHR; a data summarization tool meant to give radiologists, cardiologists and others patient-specific clinical information when they're interpreting imaging studies; a decision support tool to enable physicians to integrate imaging data with other clinical information; the new MedyMatch "Brain Bleed" App, a cognitive image review tool intended to help ER docs diagnose strokes or brain bleed in trauma patients based on evidence in their patient records.
Getting treatment for heart disease depends on a diagnosis from doctors, who can occasionally miss the subtle signs of trouble. IBM thinks it can help those doctors through artificial intelligence -- namely its Watson technology famous for besting Jeopardy champions and researching cancer. The company announced the introduction of its newest feature as part of its broader expansion of Watson Health's medical imaging initiative, which will now include 24 healthcare organizations around the world. This is a different challenge for Watson. For the first time, IBM's technology will be looking over medical data that includes images such as ultrasounds, x-rays and other types of visuals used by medical professionals.